ROCURONIUM BROMIDE INJECTION SOLUTION

Țară: Canada

Limbă: engleză

Sursă: Health Canada

Ingredient activ:

ROCURONIUM BROMIDE

Disponibil de la:

STERIMAX INC

Codul ATC:

M03AC09

INN (nume internaţional):

ROCURONIUM BROMIDE

Dozare:

10MG

Forma farmaceutică:

SOLUTION

Compoziție:

ROCURONIUM BROMIDE 10MG

Calea de administrare:

INTRAVENOUS

Unități în pachet:

10X5ML

Tip de prescriptie medicala:

Prescription

Zonă Terapeutică:

NEUROMUSCULAR BLOCKING AGENTS

Rezumat produs:

Active ingredient group (AIG) number: 0126317001; AHFS:

Statutul autorizaţiei:

APPROVED

Data de autorizare:

2023-03-02

Caracteristicilor produsului

1
PRODUCT MONOGRAPH
PR
ROCURONIUM BROMIDE INJECTION
10MG/ML STERILE SOLUTION FOR INJECTION
NON-DEPOLARIZING SKELETAL NEUROMUSCULAR BLOCKING AGENT
Strides Pharma Canada Inc.
1565, Boul. Lionel-Boulet
Varennes, Quebec
Canada J3X 1P7
Submission Control No.: 239118
May
14
, 2020
Date of
Revision:
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................................
3
SUMMARY
PRODUCT
INFORMATION
...........................................................................................................
3
INDICATIONS
AND
CLINICAL
USE
.................................................................................................................
3
CONTRAINDICATIONS
.......................................................................................................................................
3
WARNINGS
AND
PRECAUTIONS
.....................................................................................................................
4
ADVERSE
REACTIONS
.......................................................................................................................................
8
DRUG
INTERACTIONS
......................................................................................................................................
10
DOSAGE
AND
ADMINISTRATION
..................................................................................................................
12
OVERDOSAGE
....................................................................................................................................................
17
ACTION
AND
CLINICAL
PHARMACOLOGY
..............................................................................................
17
STORAGE
AND
STABILITY
.............................................................................................................................
24
SPECIAL
HANDLING
INSTRUCTIONS
............................................................................................